Cascade Financial Partners LLC Takes $220,000 Position in Exelixis, Inc. $EXEL

Cascade Financial Partners LLC purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the 2nd quarter, HoldingsChannel reports. The firm purchased 5,000 shares of the biotechnology company’s stock, valued at approximately $220,000.

A number of other hedge funds also recently bought and sold shares of the business. Envestnet Asset Management Inc. increased its position in shares of Exelixis by 23.9% in the first quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company’s stock valued at $9,159,000 after buying an additional 47,845 shares in the last quarter. Stratos Wealth Partners LTD. acquired a new stake in Exelixis in the 1st quarter valued at $234,000. Cerity Partners LLC grew its stake in Exelixis by 127.3% in the 1st quarter. Cerity Partners LLC now owns 167,915 shares of the biotechnology company’s stock valued at $6,199,000 after acquiring an additional 94,031 shares during the period. New York State Common Retirement Fund increased its holdings in Exelixis by 2.7% in the 1st quarter. New York State Common Retirement Fund now owns 161,457 shares of the biotechnology company’s stock worth $5,961,000 after acquiring an additional 4,200 shares in the last quarter. Finally, Stephens Inc. AR raised its position in Exelixis by 721.1% during the first quarter. Stephens Inc. AR now owns 73,398 shares of the biotechnology company’s stock worth $2,710,000 after acquiring an additional 64,459 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Up 3.8%

Shares of Exelixis stock opened at $42.97 on Wednesday. Exelixis, Inc. has a 52 week low of $31.90 and a 52 week high of $49.62. The business’s fifty day simple moving average is $39.16 and its 200-day simple moving average is $40.47. The firm has a market cap of $11.52 billion, a PE ratio of 20.66, a price-to-earnings-growth ratio of 0.79 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. The firm had revenue of $597.76 million during the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The company’s quarterly revenue was up 10.8% on a year-over-year basis. During the same period last year, the company earned $0.47 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. HC Wainwright lifted their target price on shares of Exelixis from $46.00 to $49.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Cowen reiterated a “buy” rating on shares of Exelixis in a report on Wednesday, November 5th. Stifel Nicolaus set a $43.00 price objective on Exelixis in a research note on Wednesday, November 5th. Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Finally, Oppenheimer reaffirmed a “market perform” rating and issued a $36.00 price target on shares of Exelixis in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $45.45.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.